Exiqon A/S (NASDAQ OMX: "EXQ"), a leading supplier of high-value products for
gene expression analysis, and Asuragen, Inc. a fully integrated molecular
diagnostics company focused on oncology and companion diagnostics with special
capabilities in the area of miRNA, today announced the signing of a Service
Center Agreement, allowing Asuragen to provide real-time PCR services based on
Exiqon's miRCURY LNA' Universal RT microRNA PCR products.
The Asuragen Genomic Services Division provides a comprehensive range of nucleic acid-based services from biomarker discovery to development of companion diagnostics (isolation/preparation from multiple sample types, genomic profiling, miRNA/mRNA expression profiling, assay development and validation, CLIA-based clinical trial testing, bioinformatics, and regulatory services).
LNA'-based microRNA real-time PCR profiling holds great promise as a non-invasive way to discover important new biomarkers for a wide range of diseases and biological processes. Exiqon's microRNA real-time PCR system combines a Universal RT reaction with LNA'-enhanced PCR primers, which results in unmatched sensitivity and specificity for all sample types.
-Exiqon's high quality microRNA PCR products allow us to further expand our service offerings to meet the needs of our pharmaceutical and diagnostic partners-, said Carol Berry, Sr. Vice President & GM of Asuragen Genomic Services Division.
In a comment, Sr. VP Sales & Marketing, Henrik Pfundheller of Exiqon said: "We are honored and excited to support Asuragen on the discovery of novel microRNA biomarkers" and added: "Asuragen are experts in their own right in the field of microRNA and this is a great opportunity for us to expand our presence in the U.S. market."
Additional information from Asuragen Carol Berry, Sr. VP & GM, Genomic Services, tel. 1 512 681 5200, cberry@asuragen.com
Additional information from Exiqon Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101) Henrik M. Pfundheller, Senior Vice President Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090 2106)
Attachment:
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=435540
The Asuragen Genomic Services Division provides a comprehensive range of nucleic acid-based services from biomarker discovery to development of companion diagnostics (isolation/preparation from multiple sample types, genomic profiling, miRNA/mRNA expression profiling, assay development and validation, CLIA-based clinical trial testing, bioinformatics, and regulatory services).
LNA'-based microRNA real-time PCR profiling holds great promise as a non-invasive way to discover important new biomarkers for a wide range of diseases and biological processes. Exiqon's microRNA real-time PCR system combines a Universal RT reaction with LNA'-enhanced PCR primers, which results in unmatched sensitivity and specificity for all sample types.
-Exiqon's high quality microRNA PCR products allow us to further expand our service offerings to meet the needs of our pharmaceutical and diagnostic partners-, said Carol Berry, Sr. Vice President & GM of Asuragen Genomic Services Division.
In a comment, Sr. VP Sales & Marketing, Henrik Pfundheller of Exiqon said: "We are honored and excited to support Asuragen on the discovery of novel microRNA biomarkers" and added: "Asuragen are experts in their own right in the field of microRNA and this is a great opportunity for us to expand our presence in the U.S. market."
Additional information from Asuragen Carol Berry, Sr. VP & GM, Genomic Services, tel. 1 512 681 5200, cberry@asuragen.com
Additional information from Exiqon Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101) Henrik M. Pfundheller, Senior Vice President Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090 2106)
Attachment:
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=435540
© 2013 GlobeNewswire
